Cleveland, Ohio
Colorectal cancer clinical trials in Cleveland, OH
36 colorectal cancer studies are recruiting participants at sites in Cleveland as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Cleveland at a glance
- 36 studies are recruiting at a site in Cleveland.
- By phase: Phase 1 (9), Phase 1/2 (11), Phase 2 (4), Phase 2/3 (1), Phase 3 (6), No phase (3), Observational (2). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (27), university, hospital or other (7), government (2).
- Most recent update to one of these records: November 12, 2026.
Studies recruiting in Cleveland
Basic details from each study's public record (the 30 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Case Western, University Hospitals Cleveland Medical Center
- Registry record
- NCT07659795 · updated
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Solstice Oncology, Inc.
- Registry record
- NCT07808151 · updated
The Vanguard Study: Testing a New Way to Screen for Cancer
- No phase
- Ages 45 to 75
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Louis Stokes Cleveland VA Medical Center
- Registry record
- NCT06995898 · updated
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT07228832 · updated
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- No phase
- Ages 45 to 70
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Case Western Reserve University · Louis Stokes Cleveland VA Medical Center
- Registry record
- NCT05080673 · updated
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland Clinic Foundation
- Registry record
- NCT05174169 · updated
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Bayer
- Study site
- Cleveland Clinic - Oncology Department
- Registry record
- NCT06760819 · updated
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- University Hospitals Cleveland Medical Center
- Registry record
- NCT07397338 · updated
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study sites
- Cleveland Clinic Cancer Center Fairview Hospital Moll Pavilion · Taussig Cancer Insititute Cleveland Clinic · University Hospitals Cleveland Medical Center
- Registry record
- NCT06662786 · updated
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- Cleveland Clinic, Taussig Cancer Institute
- Registry record
- NCT06720987 · updated
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- University Hospital of Cleveland
- Registry record
- NCT06750094 · updated
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- UH Cleveland Medical Center
- Registry record
- NCT07542704 · updated
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Genmab
- Study site
- Cleveland Clinic
- Registry record
- NCT03526835 · updated
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Inc
- Study site
- University Hospitals - UH Cleveland Medical Center
- Registry record
- NCT07094204 · updated
Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Phase 1/2
- Ages 18 to 90
- All sexes
- Sponsor
- Perspective Therapeutics
- Study site
- Cleveland Clinic
- Registry record
- NCT06710756 · updated
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Study site
- Cleveland Clinic Foundation
- Registry record
- NCT06973564 · updated
The Cancer of the Pancreas Screening-5 CAPS5)Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Johns Hopkins University
- Study site
- Case Comprehensive Cancer Center, Case Western Medical Reserve
- Registry record
- NCT02000089 · updated
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Cleveland Clinic Foundation
- Registry record
- NCT05630794 · updated
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Institut de Recherches Internationales Servier
- Study site
- Cleveland Clinic
- Registry record
- NCT05786924 · updated
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- University Hospitals Cleveland Medical Center
- Registry record
- NCT07222800 · updated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Parabilis Medicines, Inc.
- Study sites
- Cleveland Clinic · University Hospitals Cleveland Medical Center, Seidman Cancer Center
- Registry record
- NCT05919264 · updated
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Bicara Therapeutics
- Study site
- Cleveland Clinic
- Registry record
- NCT04429542 · updated
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- PMV Pharmaceuticals, Inc
- Study site
- The Cleveland Clinic Taussig Cancer Center
- Registry record
- NCT04585750 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #10
- Registry record
- NCT05176483 · updated
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- Case Comprehensive Cancer Center
- Study site
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
- Registry record
- NCT06263088 · updated
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- EvolveImmune United, Inc
- Study site
- University Hospitals Cleveland Medical Center
- Registry record
- NCT07217171 · updated
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Guardant Health, Inc.
- Study site
- Cleveland Clinic
- Registry record
- NCT05059444 · updated
Safety of HRX215 in Patients After Minor and Major Liver Resection
- Phase 1/2
- Ages 18 to 75
- All sexes
- Sponsor
- HepaRegeniX GmbH
- Study site
- Cleveland Clinic
- Registry record
- NCT06638502 · updated
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Iambic Therapeutics, Inc
- Study sites
- Cleveland Clinic · University Hospital Cleveland Medical Center
- Registry record
- NCT06253871 · updated
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Jennifer Dorth
- Study site
- Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Center
- Registry record
- NCT07425054 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.
Ask about studies near Cleveland
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Ohio
All Ohio locations
91 studies recruiting across 54 cities.
Columbus
35 studies recruiting.
Cincinnati
30 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections